Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24225Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Kiortsis, D. N. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:39:13Z | - |
| dc.date.available | 2015-11-24T19:39:13Z | - |
| dc.identifier.issn | 0300-7995 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24225 | - |
| dc.rights | Default Licence | - |
| dc.subject | adipocytokines | en |
| dc.subject | cholesterol | en |
| dc.subject | high density lipoprotein cholesterol | en |
| dc.subject | insulin | en |
| dc.subject | lipids | en |
| dc.subject | sibutramine | en |
| dc.subject | type 2 diabetes | en |
| dc.subject | uric acid | en |
| dc.subject | weight loss | en |
| dc.subject | type-2 diabetes-mellitus | en |
| dc.subject | randomized controlled-trials | en |
| dc.subject | placebo-controlled trial | en |
| dc.subject | coronary-heart-disease | en |
| dc.subject | fatty liver-disease | en |
| dc.subject | serum uric-acid | en |
| dc.subject | weight-loss | en |
| dc.subject | obese-patients | en |
| dc.subject | double-blind | en |
| dc.subject | insulin-resistance | en |
| dc.title | A review of the metabolic effects of sibutramine | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | Doi 10.1185/030079905x38132 | - |
| heal.identifier.secondary | <Go to ISI>://000228215500017 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1185/030079905X38132 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2005 | - |
| heal.abstract | Background. Obesity is associated with an increased incidence of diabetes, hypertension, dyslipidaemia and coronary artery disease. Current management strategies of obesity include lifestyle interventions and pharmacotherapy. Sibutramine is a drug with established efficacy in weight reduction and maintenance of weight loss. It reduces food intake and attenuates the fall in metabolic rate associated with weight loss. Objective: To review the metabolic effects associated with sibutramine use. Methods: Relevant articles were identified through a Medline search (up to December 2004). Results: Weight loss with sibutramine treatment is associated with improved insulin sensitivity and a fall in glycosylated haemoglobin levels in type 2 diabetic patients. In most trials sibutramine exerted favourable effects on lipids, especially on high density lipoprotein (HDL) cholesterol and triglycerides, as well as on the total:HDL cholesterol ratio. Sibutramine also lowers serum uric acid concentrations. Furthermore, this drug seems to favourably influence adipocytokines; it reduces serum leptin and resistin levels and increases adiponectin levels. Sibutramine also exerts a beneficial effect on hyperandrogenaemia in obese women with polycystic ovary syndrome. Preliminary findings also suggest that weight loss following treatment with sibutramine is useful in patients with non-alcoholic fatty liver disease (NAFLD). Conclusion: Weight loss following sibutramine administration is associated with several favourable metabolic effects. | en |
| heal.journalName | Current Medical Research and Opinion | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
